多西紫杉醇联合顺铂与多西紫杉醇联合奈达铂治疗中晚期乳腺癌的临床对比研究

Comparison of clinical effects of docetaxel with cisplatin and with nedaplatin on advanced breast cancer

目的:探讨多西紫杉醇联合顺铂与多西紫杉醇联合奈达铂治疗中晚期乳腺癌的疗效和不良反应。方法:64例中晚期乳腺癌患者随机分为多西紫杉醇联合顺铂化疗组(TP组,32例)和多西紫杉醇联合奈达铂化疗组(TN组,32例),观察两组的近期和远期疗效以及不良反应。结果:多西紫杉醇联合顺铂与多西紫杉醇联合奈达铂化疗组的近期有效率分别为96.9%和93.75%(P>0.05)。TP组的3年生存率(70.97%)、局部复发率(15.63%)和远处转移率(6.25%)与TN组(分别为65.63%、16.13%和6.45%)相比,差异均无统计学意义(P>0.05)。TP组的胃肠毒性和肾毒性发生率高于TN组(P<0.05),而TN组的血小板减少发生率高于TP组(P<0.05)。结论:TP化疗与TN化疗均能明显提高中晚期乳腺癌患者的近期和远期疗效,并降低局部复发率和远处转移率。不良反应可以耐受。

Objective： To investigate the curative and untoward effects of the combinations of docetaxeland cisplatin / nedaplatin in the treatment of middle- advanced breast cancer. Methods： Sixty- four patients with middle- advanced breast cancer were assigned randomly and evenly into two groups： TP group（ docetaxel combined with cisplatin） and TN group（ docetaxel combined with nedaplatin）. The short- and long- term efficacy as well as the adverse reactions were observed. Results： The short- term response rates were 96. 9% in TP group and 93. 75% in TN group,respectively（ P〉0. 05）. Between these two groups,there were no statistically significant differencesin in the three- year survival（ 70. 97% vs 65. 63%）,local recurrence rate（ 15. 63% vs16. 13%） and distant metastasis rate（ 6. 25% vs 6. 45%）（ P〉0. 05）. The incidence of gastrointestinal toxicity and renal dysfunction in the TP group were higher than that in the TN group（ P〈0. 05）,while the incidence of thrombopenia was lower in the TP group（ P〈0. 05）. Conclusion： Concurrent chemotherapy with docetaxel combined with cisplatin / nedaplatin can improve both the short term and long term efficacy of treatment in middle- advanced breast cancer and reduce the local recurrence and distant metastasis as well. Adverse reactions of both treatment regimens were tolerable.